Navigation Links
'Seeing' stem cells helps in fight against peripheral arterial disease
Date:3/10/2009

SAN DIEGO, Calif. (March 10, 2009)Interventional radiologists are fitting together the puzzle pieces of how to use stem cells to create new or more blood vessels to treat peripheral arterial disease (PAD) in those individuals with extensively narrowed or clogged arteries. That puzzle may be closer to being solved in light of recent successful techniques that use simple imaging to view and locate transplanted stem cells and to confirm that they remain alive in the body once injected, notes a study presented at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

PAD, which affects about 10 million Americans, is a chronic disease that progressively restricts blood flow causing poor blood circulation (generally in the legs) and if left untreated can lead to serious medical complications, including heart attack, stroke, amputation and death. Many people can manage the symptoms of PAD and stop its progression through lifestyle changes. If lifestyle changes are not enough, additional medical treatment may be needed, including prescribed medicine to prevent blood clots, lower blood pressure and cholesterol and control pain.

Interventional radiologists treat severe cases of PAD with minimally invasive treatments, including angioplasty and insertion of stents. "However, some patients have extensive diseasewith so many blood vessels affectedthat they're difficult to treat," said Frank Wacker, M.D., interventional radiologist at Johns Hopkins School of Medicine in Baltimore, Md. That's where stem cellsand image-guided stem cell therapycome in. "One day, stem cells may enable the targeted delivery of cellular treatments to PAD patients who may be facing amputation and death. It will be important to deliver the right amount of drug treatment to the right place, thus allowing tailored treatment for individual patients," said Wacker. "The use of C-arm CT for image-guided delivery in the angio lab enabled us to precisely target cell del
'/>"/>

Contact: Maryann Verrillo
mverrillo@SIRweb.org
703-460-5572
Society of Interventional Radiology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Seeing Alzheimers amyloids
2. Crystal (eye) ball: Study says visual system equipped with future seeing powers
3. Seeing through the skin
4. ESF EURYI award winner aims to stop cancer cells reading their own DNA
5. Newly created cancer stem cells could aid breast cancer research
6. AIDS interferes with stem cells in the brain
7. Clemson scientists shed light on molecules in living cells
8. Social habits of cells may hold key to fighting diseases
9. UF scientists reveal how dietary restriction cleans cells
10. Human derived stem cells can repair rat hearts damaged by heart attack
11. Scientists identify embryonic stem cells by appearance alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)PHILADELPHIA Mexican-American adolescents exposed to cigarette smoking scenes in movies are more likely to pick up the habit themselves, and this may be part of the acculturation process associated w
(Date:12/2/2009)PHILADELPHIA Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researc
(Date:12/2/2009)Recalls of ground beef, peanut butter, and other foods have done more than raise public awareness and concern about food safety. They also are quietly fueling a boom in the market for food testing equ
Breaking Biology News(10 mins):Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Ligon Discovery Announces Appointment of Errol B De Souza as Executive Chairman 6480 1Ligon Discovery Announces Appointment of Errol B De Souza as Executive Chairman 6480 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 1NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 3Burnout and mental distress strongly related to errors by US surgeons 61962 1Burnout and mental distress strongly related to errors by US surgeons 61962 2
...National Institutes of Health (NIH) has awarded $4...search projects that could have an extraordinarily...grants, from a new program called EUREKA (for Exce...e Acceleration), targets investigators who are tes...ing major methodological or technical advances. E...
...rs for the detection of diseases including cancer ...ne this week in Cell Research . The findings pave...ic tool. , miRNAs are a class of naturally occurr...th cancer development. Recent studies reporting in...ic cancers were unable to rule out the possibility...
... released outside of their native ranges to contro...found that through complex community interactions ...ence of an introduced fly may exacerbate the effec...The authors report their results in the September ... Spotted knapweed, a flowering plant native to Eu...
Other Biology News:NYU Cancer Institute researcher among first NIH EUREKA award recipients 2Biocontrol insect exacerbates invasive weed 2Biocontrol insect exacerbates invasive weed 3
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,("Emerald Dairy" or the "Company") (OTC Bulletin Board: EMDY), a leading,producer and distributor of infant and children,s formul
(Date:12/2/2009)The Scientist, a leading scientific magazine covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s “Top 10 Inn
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Dutch Biotech Company Pepscan Appoints New CEO 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
..., March 12 Micromet, Inc. (Nasdaq: MITI ), a bi...ary antibodies for the treatment of cancer, inflam...at it is regaining from its partner MedImmune the ...antibody candidate, blinatumomab, also known as MT...linical trial with blinatumomab for the treatment ...
... 12 Albert Liou, Corporate Vice President and Gen...national Corporation (Nasdaq: PRXL ), a leading ...resent "The True Value of Incorporating Asia into ...Medical Asia 2009 conference, to be held March 16 ...onvention & Exhibition Centre in Singapore. Mr...
...nds to acquire all outstanding shares of Genentech...nd early development to operate as an independent ...rters of combined U.S. commercial operations; Gene...novation will be enhanced through a diversity of r..., partnerships and other key assets , , -- Transa...
Other Biology Technology:Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 2PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 3PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 2Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 3Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 5Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 6Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 7
...Flow Perm/Wash Buffer I can be used in intracellul...ling proteins to permeabilize cells and to serve a...e saponin-mediated cell permeabilization is a reve...in the presence of saponin during intracellular st...
Mouse Anti-Human PREB Polyclonal Antibody, Unconjugated from Abnova Corporation
Mouse Anti-Human ACTN4 Monoclonal Antibody, Unconjugated, Clone 4D10 from Abnova Corporation
...iendly Eppendorf Thermomixer R offers maximum appl...equire shaking, heating, and cooling. Its active h...pplication and temperature control ranges. Five di...4 micro test tubes, are available for: 0.5 ml, 1.5...
Biology Products: